Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Sirolimus

FDA-approved product (solution, oral), marketed as Fyarro, Hyftor, Rapamune and 1 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Sirolimus
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Adenoma sebaceum
  • Angiofibroma
  • Cancer
  • Delayed Graft Function
  • Eye disease
  • Kidney transplant
  • Neoplasm
  • Tuberous sclerosis

Indications ChEMBL records as approved, from FDA and DailyMed labels.

WHO therapeutic group
Mammalian target of rapamycin (mtor) kinase inhibitors; Other ophthalmologicals
FDA pharmacologic class
Kinase Inhibitor; mTOR Inhibitor Immunosuppressant FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA, K. pneumoniae and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA65.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli51.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae43.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis62.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Sirolimus in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Sirolimus with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Rapamycin for Immunosuppression and B Cell Modulation Post Stem Cell Transplant for Acute Lymphoblastic Leukemia (ALL)

    NCT00795886 · start 2005-08

    Registered record
    Registry ID
    NCT00795886
    Conditions
    Acute Lymphoblastic Leukemia
    Interventions
    RAPAMYCIN
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2005-08
    Completion
    2010-03
    Enrolment
    63

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Lymphoblastic Leukemia
    InterventionRAPAMYCIN
    PhasePhase 2
    Registry statusCompleted

  • Efficacy and Safety of Everolimus With Enteric-Coated Mycophenolate Sodium (EC-MPS) in a Cyclosporine Microemulsion-free Regimen Compared to Standard Therapy in de Novo Renal Transplant Patients

    NCT00154310 · start 2005-06

    Registered record
    Registry ID
    NCT00154310
    Conditions
    Renal Transplantation
    Interventions
    Everolimus; Cyclosporine; Enteric-coated mycophenolate sodium; Corticosteroids
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2005-06
    Completion
    2008-09
    Enrolment
    300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRenal Transplantation
    InterventionEverolimus; Cyclosporine; Enteric-coated mycophenolate sodium; Corticosteroids
    PhasePhase 4
    Registry statusCompleted

  • Islet Allotransplantation With Steroid Free Immunosuppression

    NCT00446264 · start 2003-05

    Registered record
    Registry ID
    NCT00446264
    Conditions
    Type 1 Diabetes; Hypoglycemia; Metabolic Diseases
    Interventions
    islet transplantation; daclizumab - sirolimus - tacrolimus
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2003-05
    Completion
    2009-02
    Enrolment
    14

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionType 1 Diabetes; Hypoglycemia; Metabolic Diseases
    Interventionislet transplantation; daclizumab - sirolimus - tacrolimus
    PhasePhase 2
    Registry statusCompleted

  • Pre Transplant Rapamycin Treatment in Islet Transplantation Alone

    NCT01060605 · start 2001-10

    Registered record
    Registry ID
    NCT01060605
    Conditions
    Diabetes Mellitus, Type 1
    Interventions
    rapamycin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2001-10
    Completion
    2009-09
    Enrolment
    11

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetes Mellitus, Type 1
    Interventionrapamycin
    PhasePhase 3
    Registry statusCompleted

  • Renal Function Optimization With Mycophenolate Mofetil (MMF) Immunosuppressor Regimes (ALHAMBRA)

    NCT00290069

    Registered record
    Registry ID
    NCT00290069
    Conditions
    Kidney Diseases; Graft Rejection
    Interventions
    Tacrolimus; Rapamycin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    94

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionKidney Diseases; Graft Rejection
    InterventionTacrolimus; Rapamycin
    PhasePhase 4
    Registry statusUnknown